approval of Eliquis (ELL-eh-kwiss, apixaban) will intensify the marketing war among the NEW oral anticoagulants

February 2013

The approval of Eliquis (ELL-eh-kwiss, apixaban) will intensify the marketing war among the NEW oral anticoagulants.

Eliquis will join Pradaxa (dabigatran) and Xarelto (rivaroxaban) as warfarin alternatives for preventing strokes in atrial fib.

Keep in mind how the new oral anticoagulants stack up for A fib.

Get concise, unbiased advice for effective drug therapy, plus CE/CME

Prescriber Insights: PA includes:

Cutting-edge advice about new medications and how they fit into practice
Unbiased, evidence-based, 100% free of financial support from the pharma industry written by your peers
Side-by-side comparisons of drugs by class or disease state, plus FAQs, pros/cons, and simple recommendations

Already a subscriber? Log in

Volume pricing available. Get a quote